Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
04:36pm, Friday, 24'th Feb 2023 Zacks Investment Research
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus
04:48pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.
Nicholas Ward's Dividend Growth Portfolio: January 2023 Review
02:35am, Thursday, 23'rd Feb 2023
My dividend income rose by 9.56% on a y/y basis during January. My portfolio's value rose by approximately 6.9%.
This Recession-Proof Company Has a Best-in-Class Dividend
12:30pm, Wednesday, 22'nd Feb 2023 The Motley Fool
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.
Bristol Myers: Looking Good For 2023
12:32pm, Tuesday, 21'st Feb 2023
Bristol Myers has seen a recent pullback in its share price, just like many other big pharma names. The company has been hit by loss of exclusivity of Revlimid, but is able to stabilize sales amidst n
What To Expect From Bristol-Myers Squibb In 2023
05:43am, Monday, 20'th Feb 2023
Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
01:14pm, Saturday, 18'th Feb 2023 The Motley Fool
These pharmaceutical stocks probably won't stay so attractively valued for too much longer.
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
08:14am, Saturday, 18'th Feb 2023
These pharmaceutical stocks probably won't stay so attractively valued for too much longer.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
02:40pm, Friday, 17'th Feb 2023 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
11:17am, Friday, 17'th Feb 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
08:00am, Friday, 17'th Feb 2023
It's a new day at Bristol Myers, according to a company exec. But the drug giant's stock remains under pressure ahead of a patent cliff.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
5 Least-Hurt Biotech ETFs of the Last Week
06:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
5 Least-Hurt Biotech ETFs of the Last Week
02:18pm, Wednesday, 15'th Feb 2023
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
05:01pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
